Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Holding AU:AVE?
Track your performance easily
AVE Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week Range― - ―
Previous CloseAU$0.01
Volume1.20M
Average Volume (3M)N/A
Market Cap
AU$9.51M
Enterprise ValueAU$8.29M
Total Cash (Recent Filing)AU$1.47M
Total Debt (Recent Filing)AU$246.07K
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume982,832
30 Day Avg. VolumeN/A
Standard Deviation0.46
R-Squared0.12
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)6.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Avecho Biotechnology Limited News
PremiumCompany Announcements
Avecho Biotechnology Expands Trials and ManufacturingPremiumCompany Announcements
Avecho Biotech Reports Decreased Revenue and Rising Losses
PremiumCompany Announcements
Avecho Biotech Advances Insomnia Treatment Trial
PremiumCompany Announcements
Avecho Biotechnology AGM Approves Key Resolutions
PremiumCompany Announcements
Avecho Biotechnology Spotlights Innovative TPM® System
PremiumCompany Announcements
Avecho Biotechnology Options Cease as Conditions Lapse
PremiumCompany Announcements
Avecho Begins Landmark Insomnia Treatment TrialPremiumCompany Announcements
Avecho Launches Landmark Insomnia Treatment TrialOptions Prices
Currently, No data available
---
Ownership Overview
0.36%
Insiders
― Other Institutional Investors
99.64% Public Companies and
Individual Investors
AVE FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Currently, no data Available
What is Avecho Biotechnology Limited’s market cap?
Currently, no data Available
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Feb 27, 2025 which is in 106 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Aug 26, 2024. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,169,297,000 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in AU:AVE
---
Avecho Biotechnology Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-108.69%
Trailing 12-Months
Asset Growth
49.53%
Trailing 12-Months
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
---
---